Vol 54, No 6 (2020)
Research Paper
Published online: 2020-11-17

open access

Page views 2657
Article views/downloads 817
Get Citation

Connect on Social Media

Connect on Social Media

Mechanical thrombectomy for acute ischaemic stroke during therapeutic anticoagulation: long-term outcomes

Klaudia Nowak12, Ewa Włodarczyk2, Karolina Porębska1, Żaneta Chatys-Bogacka1, Jeremiasz Jagiełła1, Roman Pułyk2, Joanna Słowik3, Tadeusz Popiela4, Agnieszka Słowik12
Pubmed: 33202029
Neurol Neurochir Pol 2020;54(6):538-543.


Aim of study. Mechanical thrombectomy (MT) is one of the aetiological treatment options recommended for anticoagulated patients with acute ischaemic stroke (AIS). We analysed its long-term outcomes using the modified Rankin Score (mRS) or mortality on day 90.

Clinical rationale for the study. Data describing the anticoagulant efficacy and safety of MT in patients with AIS is limited.

Materials and methods.
This study included 291 patients with AIS (49% women, mean [SD] age 66 [15] years) who underwent MT in the Comprehensive Stroke Centre in Krakow, Poland. Data describing demographics, stroke risk factors, NIHSS on admission, postprocedural thrombolysis in cerebral infarction score, 24-hour postprocedural haemorrhagic transformation (ECASS-2) as seen on computed tomography, and time between stroke onset and groin puncture was collected. The outcome measure was the mRS on day 90 after stroke onset (a favourable outcome was defined as an mRS not exceeding 2 points; an unfavourable outcome was death).

Thirty-seven patients (13%) were on therapeutic anticoagulation during MT. Univariate analysis showed that anticoagulated patients were older and more likely to have been diagnosed with hypertension, ischaemic heart disease, or atrial fibrillation. The patient groups did not differ in terms of clot location, postprocedural thrombolysis in cerebral infarction score, haemorrhagic transformation on computed tomography, or mRS on day 90. Multivariate logistic regression analysis showed that younger age, male sex, no history of diabetes mellitus, lower NIHSS score on admission, shorter time between stroke onset and groin puncture, and better recanalisation were associated with favourable outcomes at day 90, and that therapeutic anticoagulation was not (OR, 1.00; 95%CI, 0.46-2.15; p = 0.99). Anticoagulation did not affect mortality at day 90 (OR, 1.28; 95%CI, 0.56-2.92; p = 0.55).

Conclusion and clinical implications.
In anticoagulated patients with AIS, MT does not affect long-term outcomes.

Article available in PDF format

View PDF Download PDF file


  1. Freedman B, Porpara TS, Lip GY. Stroke prevention in atrial fibrillation. Lancet. 2016; 388: 806–17.
  2. Alberts M, Eikelboom J, Hankey G. Antithrombotic therapy for stroke prevention in non-valvular atrial fibrillation. The Lancet Neurology. 2012; 11(12): 1066–1081.
  3. Powers WJ, Rabinstein AA, Ackerson T, et al. 2018 Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Journal of Vascular Surgery. 2018; 67(6): 1934.
  4. Correction to: Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2019; 50(12): e440–e441.
  5. Nowak K, Derbisz J, Jagiełła J, et al. Time from stroke onset to groin puncture affects rate of recanalisation after mechanical thrombectomy: a real-life single centre experience. Neurol Neurochir Pol. 2020; 54(2): 156–160.
  6. Yaghi S, Willey JZ, Cucchiara B, et al. American Heart Association Stroke Council; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; and Council on Quality of Care and Outcomes Research. Treatment and Outcome of Hemorrhagic Transformation After Intravenous Alteplase in Acute Ischemic Stroke: A Scientific Statement for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2017; 48(12): e343–e361.
  7. Lattanzi S, Silvestrini M. Future challenges of stroke treatment. Neurol Neurochir Pol. 2018; 52(3): 415–416.
  8. Łabuz-Roszak B, Starostka-Tatar A, Lasek-Bal A, et al. Diagnostics, treatment and secondary prevention of ischemic stroke in the Silesian Province, Poland between 2009 and 2015. Neurol Neurochir Pol. 2018; 52(2): 235–242.
  9. Wiącek M, Kaczorowski R, Sieczkowski B, et al. Mechanical thrombectomy: Determining the proportion of eligible acute ischemic stroke patients in the cohort of single academic stroke center. Neurol Neurochir Pol. 2018; 52(3): 359–363.
  10. Purrucker JC, Wolf M, Haas K, et al. Safety of Endovascular Thrombectomy in Patients Receiving Non-Vitamin K Antagonist Oral Anticoagulants. Stroke. 2016; 47(4): 1127–1130.
  11. Zapata-Wainberg G, Ximénez-Carrillo Á, Trillo S, et al. Madrid Stroke Network. Mechanical thrombectomy in orally anticoagulated patients with acute ischemic stroke. J Neurointerv Surg. 2018; 10(9): 834–838.
  12. Uphaus T, Singer OC, Berkefeld J, et al. Safety of endovascular treatment in acute stroke patients taking oral anticoagulants. Int J Stroke. 2017; 12(4): 412–415.
  13. De Marchis GM, Jung S, Colucci G, et al. Intracranial hemorrhage, outcome, and mortality after intra-arterial therapy for acute ischemic stroke in patients under oral anticoagulants. Stroke. 2011; 42(11): 3061–3066.
  14. Benavente L, Larrosa D, García-Cabo C, et al. Safety and Efficacy of Mechanical Thrombectomy in Acute Ischemic Stroke of Anticoagulated Patients-A Prospective Observational Study. J Stroke Cerebrovasc Dis. 2016; 25(9): 2093–2098.
  15. Rebello LC, Haussen DC, Belagaje S, et al. Endovascular Treatment for Acute Ischemic Stroke in the Setting of Anticoagulation. Stroke. 2015; 46(12): 3536–3539.
  16. Seiffge DJ, Hooff RJ, Nolte CH, et al. NOACISP Study Group*. Recanalization therapies in acute ischemic stroke patients: impact of prior treatment with novel oral anticoagulants on bleeding complications and outcome. Circulation. 2015; 132(13): 1261–1269.
  17. Wong JWP, Churilov L, Dowling R, et al. Safety of Endovascular Thrombectomy for Acute Ischaemic Stroke in Anticoagulated Patients Ineligible for Intravenous Thrombolysis. Cerebrovasc Dis. 2018; 46(5-6): 193–199.
  18. Kurowski D, Jonczak K, Shah Q, et al. Safety of Endovascular Intervention for Stroke on Therapeutic Anticoagulation: Multicenter Cohort Study and Meta-Analysis. J Stroke Cerebrovasc Dis. 2017; 26(5): 1104–1109.
  19. Endovascular Therapy for Ischemic Stroke. New England Journal of Medicine. 2015; 372(24): 2363–2366.
  20. Campbell BCV, Mitchell PJ, Kleinig TJ, et al. EXTEND-IA Investigators. Endovascular therapy for ischemic stroke with perfusion-imaging selection. N Engl J Med. 2015; 372(11): 1009–1018.
  21. Haas K, Purrucker JC, Rizos T, et al. Rationale and design of the Registry of Acute Stroke Under Novel Oral Anticoagulants-prime (RASUNOA-prime). Eur Stroke J. 2019; 4(2): 181–188.
  22. Meinel TR, Frey S, Arnold M, et al. Clinical presentation, diagnostic findings and management of cerebral ischemic events in patients on treatment with non-vitamin K antagonist oral anticoagulants - A systematic review. PLoS One. 2019; 14(3): e0213379.
  23. Liu M, Zheng Y, Li G. Safety of Recanalization Therapy in Patients with Acute Ischemic Stroke Under Anticoagulation: A Systematic Review and Meta-Analysis. J Stroke Cerebrovasc Dis. 2018; 27(9): 2296–2305.